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Abstract
Background: VHZ is a VH1-like (member Z) dual specific protein phosphatase encoded by DUSP23 gene. Some of the 
dual specific protein phosphatases (DSPs) play an important role in cell cycle control and have shown to be associated 
with carcinogenesis. Here, the expression of VHZ associated with cell growth and human cancers was investigated.
Results: We generated a mouse monoclonal antibody (mAb clone#209) and rabbit polyclonal antibodies (rAb) against 
VHZ. We performed cell proliferation assay to learn how VHZ is associated with cell cycle by retroviral transduction to 
express VHZ, VHZ(C95S), and control vector in MCF-7 cells. Overexpression of VHZ [but not VHZ(C95S)] in MCF-7 cells 
promoted cell proliferation compared to control cells. shRNA-mediated knockdown of VHZ in MCF-7 cells showed that 
reduction of VHZ resulted in increased G1 but decreased S phase cell populations. Using indirect immunofluorescence, 
we showed that both exogenous and endogenous VHZ protein was localized at the centrosome in addition to its 
cytoplasmic distribution. Furthermore, using immunohistochemistry, we revealed that VHZ protein was overexpressed 
either in enlarged centrosomes (VHZ-centrosomal-stain) of some invasive ductal carcinomas (IDC) Stage I (8/65 cases) 
or in entire cytoplasm (VHZ-cytosol-stain) of invasive epithelia of some IDC Stage II/III (11/47 cases) of breast cancers 
examined. More importantly, upregulation of VHZ protein is also associated with numerous types of human cancer, in 
particular breast cancer. VHZ mAb may be useful as a reagent in clinical diagnosis for assessing VHZ positive tumors.
Conclusions: We generated a VHZ-specific mAb to reveal that VHZ has a novel subcellular localization, namely the 
centrosome. VHZ is able to facilitate G1/S cell cycle transition in a PTP activity-dependent manner. The upregulation of 
its protein levels in primary human cancers supports the clinical relevance of the protein in cancers.
Introduction
Aberrant protein tyrosine phosphorylation can result
from the dysregulated expression of protein tyrosine
kinases (PTKs) or protein tyrosine phosphatases (PTPs)
[1]. Protein phosphorylation and dephosphorylation are
major regulatory events in many cellular and pathogenic
processes [2]. Considerable attention has centered on
protein kinases in cancer development, however the role
of protein phosphatases in cancer is still an under-
explored area.
In recent years, emerging evidence indicates that mem-
bers of the phosphatase of regenerating liver (PRL) sub-
group of PTPs are linked to multiple human cancers [3].
The PRL-PTP family comprises three members: PRL-1,
PRL-2, and PRL-3. Compelling evidence suggests that
each PRL-PTP member might individually participate in
the process of cancer development and metastases [1]. In
particular, PRL-3 is the most thoroughly investigated
member of this subgroup; and was first shown to be a
metastasis-associated phosphatase that is consistently
overexpressed in metastatic colorectal cancer (CRC) [4].
In an attempt to identify more PRL-PTP-related phos-
phatases, we used the human PRL-3 amino acid sequence
to perform BLAST database searches and found VHZ
that shares about 28% amino acid sequence identity with
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human PRL-PTPs. Indeed, VHZ was cloned and reported
by three independent groups in 2004 [5-7].
There are 107 known human protein tyrosine phos-
phatases (PTPs) [8]. Among these PTPs, there is a class
called dual-specific or VH1-like PTPs (http://www.
ptphome.net/resource/resource.html[8]). The VH1-like
family consists of 63 members, which comprises 19 Atyp-
ical Dual-Specific Phosphatases (DUSP), 16 Myotubular-
ins, 11 Map Kinase Phosphatases (MKPs), 5 PTEN
members, 4 CDC14 members, 3 PRLs (PRL-1, PRL-2,
and PRL-3), and a few others. VHZ belongs to the atypi-
cal DUSP and has also been referred to as DUSP23,
DUSP25, FLJ20442, LMW-DSP3. The HUGO accepted
nomenclature for this gene is DUSP23, we have referred
to DUSP23-encoded protein as VHZ since it is a member
of the VH1-like phosphatase family. VHZ is expressed in
many tissues and is located in both the cytosol and in
nucleoli [5]. It is the smallest (calculated 16-kDa) of the
catalytically active protein-tyrosine phosphatases (PTP)
[5]. The crystal structure of VHZ has recently been deter-
mined at 1.93 Å resolution [9]. Despite VHZ's remarkably
high degree of conservation throughout evolution with
orthologues in frogs, fish, fly, and the Archaea, the physi-
ological role of VHZ is still largely unknown since it was
first cloned and identified six years ago [5-7].
VHZ and VHR belong to the same subgroup of VH1-
like PTPs [8]. Since VHR has been reported to ha ve a
function in regulating cell cycle progression [10], we
attempt to investigate if VHZ also plays a role in regulat-
ing cell cycle. We revealed that VHZ has an additional
novel centrosomal localization and show that VHZ has a
capacity to enhance G1/S phase transition. Furthermore,
many dual specific protein phosphatases (DSPs), such as
MKPs [11], are associated with carcinogenesis. We also
investigated the expression levels of VHZ in multiple
human primary cancers and showed that VHZ is overex-
pressed in human cancers especially in breast cancers.
Materials and methods
Generation of VHZ-EGFP, VHZ(C95S)-EGFP, GST-VHZ 
expression constructs
The human Universal Quick-clone II cDNA library (BD,
Cat#637260) was used as template in the generation of
VHZ cDNA. Forward primer A; 5'gcgaattcaccatgggcg
tgcagccccccaacttctcc3' and reverse primer B; 5'gtggatc-
ccgtttcgttcgctggtag 3' were used to perform PCR. The
VHZ PCR fragment was then inserted into the EcoR1 and
BamH1 sites of the pEGFP-N1 vector, resulting in VHZ
C - t e r m i n a l l y  t a g g e d  w i t h  E G F P  (V H Z - E G F P ) .  T o  c o n -
struct VHZ(C95S), the above forward primer A and
reverse primer B together with a mid-reverse primer
5'gccaaagcccagagcagagtgcactcccacagc3' and a mid-for-
ward primer 5'gcgaattcaccatgggcgtgcagccccccaacttctcc3'
were used to generate catalytically inactive VHZ(C95S).
The VHZ(C95S) PCR fragment was then inserted into
the EcoR1 and BamH1 sites of the pEGFP-N1 vector to
form VHZ(C95S)-EGFP. The VHZ PCR product was also
inserted into pGEX-KG to form GST-VHZ. The authen-
ticity of all the clones was confirmed by DNA sequencing
of the coding region.
Generation of mouse monoclonal VHZ antibody (clone 
#209)
We used the ClonaCell™-HY Hybridoma Cloning Kit
(Stemcell Technologies Inc.) to generate VHZ hybrido-
mas [3]. The procedures were followed according to the
manufacturer's directions. Briefly: 1. Immunization of
BALB/c mice with GST-VHZ fusion protein. 2. Growth of
BALB/c parental myeloma cells SP2/0; 3. Preparation of
BALB/c mice for spleenocytes from immunized mice 4.
Fusion of spleenocytes with SP2/0 cells: 5. Selection and
characterizations of the hybridoma clones. Over 500 sur-
viving hybridoma clones were isolated and grown. By
ELISA, 75 clones showed good reactions with VHZ. We
searched for the best hybridoma clone that could be used
for multiple applications such as ELISA, WB, IF, IHC.
Finally, VHZ clone (#209) with the strongest reactivity
was selected for further studies. Rabbit polyclonal anti-
VHZ serum was generated (Genemed Synthesis, Inc.) by
immunizing rabbits with a synthetic peptide C-RRLRPG-
SIETYEQEK corresponding to amino acid residues 126-
140 of human VHZ. Antibodies were purified using Pro-
tein A followed by peptide affinity chromatography.
Generation of ascetic fluids
Hybridoma cells (5 × 106) were suspended in 200 μl of
serum-free DMEM medium and injected with a 26-gauge
needle into the peritoneal cavity. After 10 days, the
mouse developed a large quantity of ascetic fluid, and the
abdomen was greatly distended. The mouse was sacri-
ficed and a small shallow was cut to open the abdominal
cavity. The ascetic fluid was drawn with 10 ml syringe fit-
ted with an 18-gauge needle. The fluid was centrifuged at
200 g for 10 min at 4°C. The supernatant fluid was col-
lected and frozen at -70°C till further use.
Elisa assay
GST-VHZ or pure GST antigen stocks were made in car-
bonated buffer (pH 9.6). Solution (100 μl) containing an
indicated amount of antigen was added to each well and
incubated at 4°C for overnight to coat the antigen onto
the plate. The plate was then blocked with 3% bovine
serum albumin in PBS containing 0.05% Tween 20 for 30
min at 37°C. The plate was then washed thrice with PBS.
Culture medium or monoclonal antibodies were added to
each well and incubated for 40 min at 37°C. The second-
ary antibody, anti-mouse IgG conjugated with horserad-
ish peroxidase (Pierce Cat. No 31430) diluted at 1: 3000 inTang et al. Molecular Cancer 2010, 9:128
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PBS was added to each well and incubated at 37°C for 40
min. The plate was rinsed with PBS containing 0.05%
Tween-20 thrice followed by 3 washes with sterile water.
The substrate, 100 μl of Turbo-TM B™ (Pierce product
number 34022), was added to each well and incubated for
10 min at room temperature. The reaction was stopped
by adding 100 μl of concentrated H2SO4. Absorbance was
measured at 450 nm (Elisa Reader DYNATECH
MR7000).
Overexpression or shRNA-mediated knockdown of VHZ in 
MCF7 cells by retroviral transduction
The amphotropic Phoenix packaging cells (kindly pro-
vided by Nolan Lab at Stanford University) were trans-
f e c t e d  w i t h  t h e  r e t r o v i r a l  v e c t o r  o v e r e x p r e s s i n g  V H Z ,
VHZ-mutant (pBABEpuro) or shRNAs in pSU-
PER.retro.puro vector (OligoEngine) using Effectene
according to manufacturer's instruction (Roche). The
short hairpin RNA sequences (shRNAs) to suppress VHZ
expression were purchased from Origene Technologies
(Rockville, MD). The sequences for VHZ-KD-214, VHZ-
KD-215, and VHZ-KD-216 are 5'CCATGCTGGCCTG
TTACCTGGTGAAGGAG3',5'CCGGCTCCATCGAGA
CCTATGAGCAGGAG3', and 5'AAGCAGTCTTCC
AGTTCTACCAGCGAACG3' respectively. After 48 h,
the retroviral supernatants were collected, filtered (0.45
μm; Millipore) and then added onto the target MCF7
cells (HTB-22), which is a human breast cancer cell line
purchased from American Type Culture Collection
( A T C C ;  M a n as s as,  V A ) ,  i n  t h e  p r e s e n c e  o f  5  μ g / m l  o f
polybrene (Sigma-Aldrich) for 6-8 h. Infection was done
twice. The cells were then selected with puromycin (1 μg/
ml) followed by western blot to show overexpression of
VHZ or VHZ-mut in MCF7 cells. These cell clones were
seeded out in 6-well plates and the numbers of cell were
counted from second day to fifth day. The VHZ knock-
down MCF7 cells were analyzed using bromodeoxyuri-
dine (BrdU) incorporation assay to assess the population
of cells in the S phase. Briefly, the cells were incubated
with BrdU for 15 mins and the incorporated BrdU was
detected by flow cytometric analysis using BrdU Flow Kit
from BD Pharmingen.
Colony formation assay
Cells (10,000) are seeded out in 6-well plates to form col-
onies in 2 weeks. Colonies are fixed with acetic acid and
methanol (10% v/v each) for 15 minutes, stained with
0.4% crystal violet in 20% ethanol for 30 mins and rinsed
with water to remove extra dye.
FACS analyses
Cells were dissociated by trypsin treatment and washed
once with PBS and fixed with 70% ethanol overnight at
4°C. The cells were then centrifuged and washed twice in
2 ml of PBS. The cell pellet was resuspended in PBS and
treated with 100 μg/ml RNase A (QIAGEN). 50 μg/ml
propidium iodide was added just before FACS analysis
(Becton Dickinson, NJ, USA). Acquired data were ana-
lyzed by WinMDI 2.8 software to determine the percent-
age of cells in different cell cycle stages.
Analysis of exogenous VHZ-EGFP subcellular localization in 
NRK cells
NRK cells (ATCC CRL-6509) transfected with VHZ-
EGFP expressing constructs were grown on coverslips
and washed once with PBSCM (PBS containing 1 mM
MgCl2 and 1 mM CaCl2). Cells were then fixed with
100% methanol for 15 mins at -20°C. The methanol fixa-
tion can reduce the cytosomal VHZ to clearly reveal the
centrosomal VHZ signals. After two washes with
PBSCM, the cells were permeabilized for 15 mins with
0.12% Saponin in PBSCM and incubated with rabbit anti-
pericentrin antibody from Covance' Inc (Princeton, NJ)
for 1 hour at room temperature (RT), and then overnight
at 4°C. The cells were gently washed three times with
PBSCM and incubated with anti-mouse IgG conjugated
with Texas Red (Sigma) for 4 hrs at RT. The VHZ-EGFP
was directly visualized under fluorescence microscopy.
Confocal imaging was performed (Zeiss LSM 510 image
Browser).
Analysis of endogenous VHZ in NRK, MCF-10A, and MCF-7 
cells
The NRK cells, Human Mammary Epithelial MCF-10A
(ATCC CRL-10317), and MCF-7 cells were grown on
c o v e r s l i p s  a n d  w a s h e d  o n c e  w i t h  P B S C M .  C e l l s  w e r e
fixed in 2.7% paraformaldehyde for 20 min at RT or 24°C.
Similar steps as described in the above section were fol-
lowed. Anti-γ-tubulin antibody was obtained from
Sigma. Anti-pericentrin antibody was purchased from
Abcam.
Histopathologic Analyses with Immunohistochemistry 
(IHC)
The immunohistochemistry was performed as previously
described [3]. Positive signals were detected by staining
with 3,3'-diaminobenzidine chromogen (Dako, Carpinte-
ria, CA). 80 formalin-fixed and paraffin-embedded surgi-
cal specimens of primary human breast cancer samples
were collected from the archives of the Pathology Depart-
ment of the Henan Medical Hospital. In addition, 32
human breast carcinoma tissues (CC08-02) were pur-
chased from Cybrdi (Frederick, MD). Majority of the tis-
sues were purchased from Cybrdi, Inc. (Rockville,
Maryland 20850 USA: http://cybrdi.com/index.php) and
include a major solid tumors tissue array (CC00-01-006);
squamous cell carcinoma (CC00-01-009); lung carcinoma
(CC04-01-006); colon adenocarcinoma (Grade I~III)
with normal tissue controls (CC05-01-001); pancreaticTang et al. Molecular Cancer 2010, 9:128
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carcinoma (Duct adenocarcinoma/islet cell carcinoma/
mucinous carcinoma) with normal controls (CC14-01-
001).
Findings and Discussion
Generations of VHZ mAb (clone #209)
There is a high degree of homology within the DUSP pro-
tein family, it is therefore difficult to generate specific
antibodies that do not cross-react with other DUSP pro-
teins. ClonaCell™-HY Hybridoma Cloning Kit http://
www.biowish.com/system/uploadtechN/
DC22L44J9P.pdf was used to generate the VHZ hybri-
doma. After fusing spleenocytes derived from mouse
immunized with GST-VHZ protein with SP2/0 myeloma
cells, 502 surviving hybridoma clones were isolated and
grown in culture. By ELISA, 75 clones showed good reac-
tions with VHZ were subjected to evaluation by several
critical tests. Only one clone (#209) was finally selected as
the best since it can be used for multiple applications
(ELISA, WB, IF, and IHC) (Figure 1A). The mAb secreted
by clone #209 hybridoma was extensively characterized.
The property and its uses (folds of dilution of ascetic
fluid) in various applications were summarized. The mul-
tiple applications of the VHZ mAb were shown through-
out this study (Elisa data in Additional file 1, Additional
file 2). The VHZ specific antibody will be beneficial to the
community of the researchers in this field.
Overexpression of VHZ enhances cell proliferation in MCF-7 
cells
To test if VHZ plays a role in cell cycle regulation, we gen-
erated three MCF-7 stable pools that express control vec-
tor, VHZ, and VHZ(C95S) respectively by retroviral
transduction. Lysates of puromycin-selected cells derived
from the cells were analyzed by western blot using VHZ
(#clone 209) mAb (Figure 1B) to show the levels of VHZ
and VHZ-mut were comparable (Figure 1B, lane 2-3) and
the sizes of exogenous VHZ and VHZ-mut protein (lane
2-3) were identical to the size of endogenous VHZ (lane
1). The three stable pools were then subjected to assess
for their cell proliferation (Figure 1C), the number of cells
(×1000) were plotted over the time of culture. VHZ-
expressing cells clearly enhanced cell proliferation (Figure
1C) and colony formation (Figure 1D) as compared to
control and VHZ-mut expressing MCF7 cells.
Knockdown of VHZ retards G1/S transition in MCF-7
We then carried out knockdown of VHZ in MCF-7 cells
which were transduced with the control (Figure 2A, lane
1) and various shRNAs (lanes 2-4) targeting different sites
of VHZ mRNA. Cell lysate was assessed by western blot
to evaluate the efficiency of knockdown. The western blot
(with VHZ mAb clone #209) results demonstrated that
the levels of VHZ protein in KD-215 and KD-216 cells
were much reduced compared to KD-214 cells (Figure
2A, lane 2). Interestingly, cells with efficient VHZ knock-
down (KD-215 and KD-216 Figure 2A, lane 3-4) exhib-
ited decrease in DNA replication as assessed by BrdU
incorporation (Figure 2B), which was accompanied with
increased population of cells in the G1 phase and
decreased population of cells in the S phase (Figure 2C).
These results indicate that knockdown of VHZ retarded
cell cycle progression from G1 to S phase and are consis-
tent with the observation that VHZ overexpression
enhanced cell proliferation (Figure 1). Overall, the data
support that VHZ may facilitate G1-S transition during
cell cycle, and have the ability to promote cell prolifera-
tion.
Figure 1 A: Characterization of VHZ mAb (clone #209). The mAb 
secreted by clone #209 hybridoma was extensively characterized. The 
property and its uses (folds of dilution for ascitic fluid) in various appli-
cations were summarized. WB: Western blot; IF: immunofluorescence; 
IHC: immunohistochemistry. (S Figure 1 for Elisa data) B: Endogenous 
VHZ was detected in cells transduced with vector control (lane 1), 
while increased levels of VHZ protein were observed in cells trans-
duced with VHZ (lane 2) or VHZ-mut (lane 3) expressing construct. The 
exogenous VHZ and VHZ-mut have identical size to endogenous VHZ 
protein (land 1). C: VHZ promotes cell proliferation. Cell growth was as-
sessed for MCF7 cells transduced with control vector, VHZ or VHZ-mut. 
The numbers of cell (×1000) were plotted over the time of culture.VHZ-
expressing cells displayed enhanced growth as compared to control 
and VHZ-mut cells. D: Colony forming assay. 10,000 cells as indicated 
were plated onto 6-well plates and grown for 2 weeks. The cells were 
then stained and images were taken.Cells expressing VHZ displayed 
enhanced ability of colony formation as compared to control and VHZ-
mut expressing cells.
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VHZ is localized at the centrosome and the cytoplasm
To understand the role of VHZ in cell cycle regulation, we
assessed the subcellular localization of VHZ by generat-
ing NRK cells that stably overexpress VHZ-EGFP. It is
worthy to point out that truncated EGFP protein is often
artificially located to the nuclei. Therefore, we observed
the VHZ-EGFP localized to the nuclei of interphase, pro-
phase, and telophase cells and appeared to redistribute to
the cytoplasm of cells undergoing metaphase (Figure 3A).
Importantly, the VHZ-EGFP was enriched in the cen-
trosomes of cells at all stages of the cell cycle, as estab-
lished by its co-localization with the pericentrin (a
centrosomal marker) (Figure 3A). The localization of
endogenous VHZ was determined by double immunoflu-
orescence labeling with affinity-purified rabbit polyclonal
anti-VHZ antibody in conjunction with mouse monoclo-
Figure 2 Knockdown of VHZ in MCF7 cells inhibits G1/S transition. A, the expression levels of VHZ in MCF7 cells transduced with the control (lane 
1) and various shRNAs (lanes 2-4) targeting different sites of VHZ mRNA were assessed by western blot. B, cell cycle analysis of MCF7-control and 
MCF7-VHZ-KD cells that have been stained for incorporated BrdU (with FITC anti-BrdU) and total DNA levels (with 7ADD). KD-215 and KD-216 cells 
showed significant reduction in the levels of BrdU incorporation. C, Comparison of the MCF7-control cells to MCF7-VHZ-KD cells in different cell cycle 
phases. KD-215 and KD-216 cells have significantly increased population of cells in G1 as well as concomitant decreased population of cells in S phase.
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nal (mAb) anti-γ-tubulin (another centrosomal marker)
antibody. Endogenous VHZ was clearly present in the
centrosomes in NRK cells where it co-localized with γ-
tubulin (Figure 3B, a-c). Anti-VHZ mAb together with
rabbit anti-pericentrin antibody also revealed that endog-
enous VHZ was co-localized to the centrosome and cyto-
plasm of MCF10A and MCF-7 cells (Figure 3B, d-i). The
localization of VHZ to the centrosomal regions, which is
of particular interest, gives some insight to the potential
role of this phosphatase.
VHZ is overexpressed in some human breast cancers.
Many human tumors show centrosomal aberrations. The
centrosome is an organelle that plays a key role in cell-
cycle progression and cell division. It organizes microtu-
bule arrays throughout the cell cycle and plays a pivotal
role in regulating cell division in meiotic and mitotic cells.
D e r e g u l a t i o n  o f  t h e  c e n t r o s o m e  o r g a n e l l e  i s  l i n k e d  t o
human genetic diseases and cancer. Indeed, many human
tumors show centrosome aberrations [12]. We hypothe-
sized that like MKPs or PRLs; VHZ phosphatase might
have similar functions in modulating the progression of
some cancers. We investigated the expression levels of
VHZ in 112 human breast cancer specimens and found
that 8 out of 65 breast cancer samples (IDC/ILC stage I)
expressed high levels of VHZ protein in the enlarged cen-
trosome (VHZ-centrosomal-stain), as shown by double
immunofluorescence with rabbit anti-VHZ and mouse
anti-γ-tubulin on the same section of the cancer sample
(Figure 4A) and by single staining with either rabbit anti-
VHZ antibody or mouse anti-γ-tubulin antibody on two
adjacent sections of the same sample (Figure 4B, a-b). In
addition to VHZ-centrosomal-staining, we also observed
a VHZ-cytoplasmic-staining pattern in a different subset
of breast cancer samples that were diagnosed as IDC
Stage II/III. 11 out of 47 of this type of breast cancer sam-
ples showed high levels of VHZ protein distributed
throughout the cytoplasm of epithelial tumor cells that
displayed a fibroblast-like morphology (Figure 4C a-b). In
the latter, it is possible that a fair amount of VHZ might
still be centrosomal but the staining could be masked by
the increased cytoplasmic staining in these tumor cells.
Tumor cells infiltrate the surrounding tissue matrices in
diverse patterns including both individual- and collec-
tive-cell-migration strategies [13,14]. In our study, we
showed that there were both individual-VHZ- (Figure 4C,
a) and collective-VHZ-cytosol-positive cells (Figure 4C,
b). Mouse VHZ mAb was used to reconfirm some of the
112 breast cancer specimens. Both rabbit and mouse
VHZ antibodies show similar results. These phenomena
might represent a relatively early onset of local invasion
within microenvironments in vivo. Hoverer , by IHC, 24
normal breast tissues used as control in human breast
carcinoma tissues (CC08-02) purchased from Cybrdi
(Frederick, MD) were shown to be all negative for VHZ.
One representative image was shown in S. Figure 2A.
Although the precise role that VHZ plays in tumor pro-
gression or cancer cell migration is not known, our data
indicate that overexpression of VHZ or its elevated activ-
ity might be a crucial early event for local invasion. We
then tested if VHZ could play a role in triggering cancer
cell migration. To study cell mobility driven by VHZ,
MCF-7 cells expressing VHZ-EGFP, or VHZ(C95S)-
EGFP were examined for cell migratory properties. As
migration of MCF-7 cells was difficult to measure using
Figure 3 Exogenous and endogenous VHZ are localized in the 
centrosome and the cytoplasm. A. VHZ-EGFP was transfected into 
NRK cells and visualized in cells at various cell cycle stages: Interphase 
(a), Prophase (b), Metaphase (c), and Telophase (d). Pericentrin is la-
beled in red and nuclei are labeled with To-pro-3 iodide in blue (a'-d'). 
The images were merged as shown (a"-d"). Bar, 10 μm. B. Endogenous 
VHZ was detected in NRK (a-c, bar, 10 μm) cells by double staining with 
affinity-purified rabbit anti-VHZ (rAb) and mouse anti-γ-tubulin anti-
bodies followed by anti-rabbit IgG conjugated with anti-rabbit-FITC 
(green) and anti-mouse IgG conjugated with anti-mouse-Texas Red. 
Endogenous VHZ was also detected in MCF10A and MCF-7 cells (d-f, 
bar, 20 μm and g-I, bar, 10 μm) by double staining with mouse anti-
VHZ (mAb) and rabbit anti-pericentrin antibodies followed by anti-
mouse IgG conjugated with anti-mouse-FITC (green) and anti-rabbit 
IgG conjugated with anti-rabbit-Texas Red.
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the conventional wound-healing or Transwell chamber
assays, we used an alterative 'Inverted Coverslip' assay
previously described [15]. As shown (S. Figure 2B a' white
arrows), MCF7-VHZ cells migrated out from the cover-
slip, while MCF-VHZ(C95S) cells remain within the cov-
erslip (S. Figure 2B b' white arrows). The results suggest
that VHZ is able to promote cell motility. Most impor-
tantly, we obtained 4 pairs of human samples (breast can-
cers matched with their respective normal breast tissues)
from 4 individuals to compare the expression of VHZ
expression levels, all 4 breast tumors showed robust VHZ
upregulation while 3 normal breast tissues showed no
expression with 1 showed low expression (Figure 4D),
indicating that VHZ is specifically overexpressed in these
breast cancers examined. This result also further con-
firmed the specificity of VHZ mAb in recognizing endog-
enous protein. The data suggest that VHZ may
potentially be a useful therapeutic target for breast can-
cer.
VHZ is elevated in a significant fraction of several types of 
human cancers
In addition to 112 breast cancers examined with rabbit
VHZ antibodies, we also reconfirmed the data with VHZ
mAb (clone #209) and obtained similar results; we fur-
ther used the specific VHZ mAb (clone #209) to examine
448 multiple human cancers (Figure 5) to determine the
expression of VHZ in other types of human cancers by
immunohistochemistry (IHC) [3]. VHZ level was ele-
vated in 17.5% (25 out of 143 cases) of colon cancers,
24.0% (20 out of 82 cases) of lung cancers, 35.0% (22 out
of 63 cases) of squamous carcinoma (such as the lip,
pharynx, vulva, cervix, and penis etc), 33.3% (17 out of 51
cases) of pancreatic cancers, 17.5% (7 out of 40 cases) of
brain cancers, 33.3% (4 out of 12 cases) of esophageal
cancers, 35.7% (5 out of 14 cases) of stomach cancers, 2
out of 6 cases of bladder cancers, 2 out of 11 cases of kid-
ney cancers, 2 out of 6 cases of skin cancers, 2 out of 6
cases of ovary cancers, 3 out of 8 cases of prostate can-
cers, and 2 out of 6 cases of testes cancers. These obser-
vations imply that VHZ overexpression may be associated
with the development or progression of various human
cancers, although the functional and clinical implications
need to be addressed by future experiments. Our VHZ
mAb will be useful as a reagent in clinical diagnosis for
VHZ expression and for research community in the field
of DUSP protein family.
Our findings reveal new insight into VHZ centrosomal
localization and elucidate its role in promoting cell prolif-
eration by participating in G1-S transition. The observed
overexpression of VHZ in human cancers especially in
breast cancer indicates that VHZ may have a proliferative
role in human cancer. Further investigation of this phos-
phatase will help to increase understanding of the molec-
Figure 4 VHZ is overexpressed in breast cancer. Breast cancer sam-
ples were assessed by indirect double IF) and IHC for VHZ expression. 
A. Double-labeling of VHZ and γ-tubulin in the same tissue section. 
VHZ (c) co-localized with γ-tubulin (b) at enlarged centrosomes (white 
arrowheads) of cells. Image c shows merged images a and b. Bar: 100 
μm. B. IHC detection of VHZ or γ-tubulin in two consecutive sections of 
the same breast cancer sample. Positive signals showed VHZ in brown. 
Similar centrosomal labeling patterns of VHZ (a) and γ-tubulin localiza-
tion (b) were indicated by the black arrows. Three rectangular areas 
boxed in overview images (a'-c', magnification ×630) were further en-
larged (×5) and shown in panels a-c, respectively. Panel c showed VHZ 
non-expressing breast cancer sample as a negative control. C. VHZ was 
overexpressed throughout the cytoplasm of dispersed epithelia in 
some breast cancer samples. Selected sections from different breast 
samples were shown in overview images (a' and b'). Three rectangular 
areas boxed in the overview images (a'-c', × 400) were further enlarged 
(×5) and shown as top panels a - c, respectively. Panel c showed one of 
the DUSP23-negative samples. Normal breast tissue showed no signals 
of VHZ protein expression (S. Figure 2A). D. A full western blot with 4 
pairs of human breast tissues showed that VHZ protein (16 kDa) was 
detected in all 4 breast tumor samples indicated, but not respective 
matched normal tissues (except 1 with low level). T = tumor tissue, 
while N = normal tissue.
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ular mechanism responsible for its pro-proliferative role.
The mAb developed and characterized here will be an
important reagent to the scientific community for further
studies on VHZ phosphatase.
Additional material
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